Former FDA Head Kessler Suggests Alternate Safety Monitoring Route
This article was originally published in The Tan Sheet
Executive Summary
FDA needs to reevaluate its premarket review process of drugs for non-life-threatening conditions, according to former Commissioner David Kessler, MD